BioTuesdays

Tag - SVB Leerink

Innate Pharma

SVB Leerink starts Innate Pharma at OP; PT $10

SVB Leerink initiated coverage of Innate Pharma (NASDAQ:IPHA) with an “outperform” rating and $10 price target. The stock closed at $6.31 on Nov. 8. Innate is a commercial stage biotech company focused on developing and...

SVB Leerink cuts Amneal Pharma to MP; PT to $3 from $4

SVB Leerink downgraded Amneal Pharmaceuticals (NYSE:AMRX) to “market perform” from “outperform” and lowered its price target to $3 from $4 after the company cut its guidance. The stock closed at $2.76 on Nov. 6. Analyst...

SVB Leerink starts Mereo BioPharma at OP; PT $8

SVB Leerink initiated coverage of Mereo BioPharma Group PLC (NASDAQ:MREO) with an “outperform” rating and price target of $8. The stock closed at $2.89 on Oct. 9. “We believe this rare disease-focused biopharma company...

Satsuma Pharmaceuticals

SVB Leerink starts Satsuma Pharma at OP; PT $20

SVB Leerink launched coverage of Satsuma Pharmaceuticals (NASDAQ:STSA) with an “outperform” rating and $20 price target. The stock closed at $10.70 on Oct. 7. STS101, Satsuma’s lead asset, is a dry-powder formulation of...

SVB Leerink ups AMAG Pharma PT to $14 from $9

SVB Leerink raised its price target for AMAG Pharmaceuticals (NASDAQ:AMAG) to $14 from $9 ahead of an FDA advisory committee meeting on Oct. 29. The stock closed at $11.50 on Oct. 4. “Based on our MEDACorp survey of 50...

T2 Biosystems

Analysts up T2 Biosystems price targets

Analysts for Alliance Global Partners and SVB Leerink raised their price targets for T2 Biosystems (NASDAQ:TTOO) following a conference call that updated multiple positive developments. Ben Haynor of AGP writes that the...

SVB Leerink cuts Mallinckrodt PT to $2 from $7

SVB Leerink reduced its price target for “market perform” rated Mallinckrodt (NYSE:MNK) to $2 from $7, reflecting a higher risk profile for the company. The stock closed at $1.59 on Sept. 5. “While we believe that the...

SVB Leerink starts Myovant Sciences at OP; PT $26

SVB Leerink initiated coverage of Myovant Sciences (NYSE:MYOV) with an “outperform” rating and $26 price target. The stock closed at $7 on Aug. 16. “Myovant’s lead product, relugolix, is poised to become the second...

Subscribe

Sign up to our weekly BioTuesdays newsletter.